Christopher Richard Anzalone insider trades: Arrowhead Pharmaceuticals (ARWR) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christopher reports to the SEC
Open-market buys and sales
39 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | ARWR | ↓ Sell | 13,187 | $66.10 | $872K | Direct | Jan 5, 2026 (3d) |
| Dec 22, 2025 | ARWR | ↓ Sell10b5-1 | 26,031 | $68.04 | $1.8M | Direct | Dec 23, 2025 (1d) |
| Dec 17, 2025 | ARWR | ↓ Sell | 85,000 | $64.04 | $5.4M | Direct | Dec 19, 2025 (2d) |
| Dec 16, 2025 | ARWR | ↓ Sell | 184,298 | $67.00 | $12.3M | Direct | Dec 16, 2025 (0d) |
| Apr 11, 2025 | ARWR | ↓ Sell | 141,122 | $10.87 | $1.5M | Direct | Apr 11, 2025 (0d) |
| Mar 13, 2025 | ARWR | ↓ Sell | 51,425 | $15.07 | $775K | Direct | Mar 17, 2025 (4d) |
| Mar 4, 2025 | ARWR | ↓ Sell | 300,000 | $17.58 | $5.3M | Direct | Mar 5, 2025 (1d) |
| Jan 2, 2025 | ARWR | ↓ Sell | 11,520 | $19.05 | $219K | Direct | Jan 6, 2025 (4d) |
| Dec 23, 2024 | ARWR | ↓ Sell | 12,563 | $19.59 | $246K | Direct | Dec 23, 2024 (0d) |
| Dec 18, 2024 | ARWR | ↓ Sell | 26,712 | $21.24 | $567K | Direct | Dec 20, 2024 (2d) |
| Jan 31, 2024 | ARWR | ↓ Sell | 57,499 | $32.35 | $1.9M | Direct | Feb 2, 2024 (2d) |
| Jan 2, 2024 | ARWR | ↓ Sell | 9,952 | $31.01 | $309K | Direct | Jan 4, 2024 (2d) |
| Dec 20, 2023 | ARWR | ↓ Sell | 12,000 | $28.54 | $342K | Direct | Dec 22, 2023 (2d) |
| Oct 25, 2023 | ARWR | ↓ Sell | 24,338 | $24.21 | $589K | Direct | Oct 27, 2023 (2d) |
| Sep 18, 2023 | ARWR | ↓ Sell | 57,755 | $28.12 | $1.6M | Direct | Sep 20, 2023 (2d) |
| May 4, 2023 | ARWR | ↓ Sell | 104,928 | $39.32 | $4.1M | Direct | May 5, 2023 (1d) |
| Feb 11, 2022 | ARWR | ↓ Sell | 146,388 | $51.91 | $7.6M | Direct | Feb 14, 2022 (3d) |
| Dec 15, 2021 | ARWR | ↓ Sell10b5-1 | 60,000 | $67.56 | $4.1M | Direct | Dec 17, 2021 (2d) |
| Oct 22, 2021 | ARWR | ↓ Sell10b5-1 | 65,000 | $65.77 | $4.3M | Direct | Oct 22, 2021 (0d) |
| Dec 9, 2020 | ARWR | ↓ Sell | 55,000 | $68.73 | $3.8M | Direct | Dec 10, 2020 (1d) |
| Oct 23, 2020 | ARWR | ↓ Sell | 100,000 | $58.21 | $5.8M | Direct | Oct 23, 2020 (0d) |
| Aug 13, 2020 | ARWR | ↓ Sell | 50,000 | $41.35 | $2.1M | Direct | Aug 14, 2020 (1d) |
| Jun 25, 2020 | ARWR | ↓ Sell | 100,000 | $38.81 | $3.9M | Direct | Jun 26, 2020 (1d) |
| Dec 24, 2019 | ARWR | ↓ Sell | 83,333 | $63.50 | $5.3M | Direct | Dec 27, 2019 (3d) |
| Dec 13, 2019 | ARWR | ↓ Sell | 183,333 | $67.15 | $12.3M | Direct | Dec 13, 2019 (0d) |
| Dec 3, 2019 | ARWR | ↓ Sell | 50,000 | $67.33 | $3.4M | Direct | Dec 4, 2019 (1d) |
| Oct 10, 2019 | ARWR | ↓ Sell | 56,325 | $31.83 | $1.8M | Direct | Oct 11, 2019 (1d) |
| Sep 25, 2019 | ARWR | ↓ Sell | 20,000 | $28.25 | $565K | Direct | Sep 27, 2019 (2d) |
| Sep 24, 2019 | ARWR | ↓ Sell | 112,650 | $28.54 | $3.2M | Direct | Sep 24, 2019 (0d) |
| Apr 3, 2019 | ARWR | ↓ Sell | 50,000 | $19.30 | $965K | Direct | Apr 5, 2019 (2d) |
| Dec 19, 2018 | ARWR | ↓ Sell | 90,000 | $13.92 | $1.3M | Direct | Dec 21, 2018 (2d) |
| Dec 12, 2018 | ARWR | ↓ Sell | 90,000 | $14.07 | $1.3M | Direct | Dec 14, 2018 (2d) |
| Nov 9, 2018 | ARWR | ↓ Sell | 81,500 | $14.39 | $1.2M | Direct | Nov 9, 2018 (0d) |
| Sep 4, 2018 | ARWR | ↓ Sell | 164,834 | $14.45 | $2.4M | Direct | Sep 5, 2018 (1d) |
| Mar 16, 2018 | ARWR | ↓ Sell | 26,000 | $7.40 | $192K | Direct | Mar 16, 2018 (0d) |
| Mar 15, 2018 | ARWR | ↓ Sell | 300,000 | $7.43 | $2.2M | Direct | Mar 15, 2018 (0d) |
| Oct 15, 2014 | ARWR | ↑ Buy | 16,000 | $6.32 | $101K | Direct | Oct 15, 2014 (0d) |
| Aug 31, 2010 | ARWR | ↑ Buy | 10,000 | $0.89 | $9K | Direct | Aug 31, 2010 (0d) |
| Aug 27, 2010 | ARWR | ↑ Buy | 10,000 | $0.89 | $9K | Direct | Aug 30, 2010 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ARWR insiders
Open-market trades in the last 12 months
About Christopher Richard Anzalone's insider trades
Christopher Richard Anzalone is Chief Executive Officer at Arrowhead Pharmaceuticals (ARWR). Since Aug 27, 2010, Christopher has reported 3 open-market purchases worth $119K and 36 sales worth $105.4M on SEC Form 4. In the last 12 months: 4 sales ($20.4M).
3 sales (10% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (23 filings), option exercises (16 filings), gifts (2 filings), shares withheld for taxes (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARWR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.